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Abstract 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
probiotics are effective in reducing symptoms of atopic dermatitis. 
 
STUDY DESIGN: Selective EBM review of three randomized, double-blind, placebo-controlled 
trials published after 2009, all English language. 
 
DATA SOURCES: All three studies were published in peer-reviewed journals found on PubMed 
and selected based on relevance to the proposed clinical question. 
 
OUTCOMES MEASURED: The main outcome measured was the percentage change in 
SCORAD index to determine severity of atopic dermatitis before and after trial through objective 
and subjective findings. Additional outcomes included DLQ index which was evaluated via 10 
questions scored on a scale of 0-3, IDQOL and DFI questionnaires directed towards evaluating 
quality of life through 10 questions scored from 0-3, and frequency and amount of corticosteroid 
used. 
 
RESULTS: Each study assessed the change in SCORAD when comparing the probiotic with the 
placebo group in those with moderate-to-severe atopic dermatitis. Gerasimov et al. found a 
SCORAD decrease of 33.7% in the probiotic group in comparison to a decrease of 19.4% in the 
placebo group and no statistically significant decrease in corticosteroid use (p=0.130). IDQOL 
and DFI decreased by 33% and 35.2% in the probiotic group and only by 19% and 23.8% in the 
placebo group, respectively. Iemoli et al. found that SCORAD and DLQ at the end of the trial 
was significantly reduced in the probiotic group (p = 0.001, p = 0.024, respectively). The study 
done by Navarro-Lopez et al. found a SCORAD change of -83% (95% CI, -95% to -70%) in the 
probiotic group and a change of -24% (95% CI, -36% to -11%) in the placebo group. Topical 
steroid use in the probiotic arm (7.7%) was significantly less compared to the placebo arm 
(10.8%). 
 
CONCLUSION: This systematic review suggests that probiotics are effective only as an 
adjunctive therapy in the reduction of clinical symptoms and topical corticosteroid use in atopic 
dermatitis. However, further research is needed to assess exclusive reduction in subjective 
symptoms. 
 
KEY WORDS: Atopic dermatitis, probiotics 
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INTRODUCTION 
Atopic dermatitis (AD) is a skin disorder with a chronic, recurrent course characterized 
by pruritus, inflammation, and skin barrier disruption. This condition typically manifests early 
during childhood and often persists into adulthood. AD poses a significant impact on quality of 
life as the pruritus can affect sleep quality and result in symptoms that may cause emotional 
stress over the course of an individual’s life. Without proper care, the affected areas can harbor 
colonization and infection by bacteria such as Staphylococcus aureus.1 This condition is 
commonly associated with asthma and allergic rhinitis as they are all considered to be atopic 
disorders. 
There is great potential for clinical impact in the field of AD treatments as it is a 
commonly diagnosed skin disorder. AD has a prevalence of approximately 3-10% in adults and 
20% of children worldwide with about half of those cases being diagnosed within the first year 
of life.2 Beyond the scope of the individual practitioner and patient, AD also poses a sizeable 
portion of healthcare costs nationwide. The annual financial cost of AD is estimated to be $5.297 
billion which includes direct (prescriptions, visits to the physician) and indirect costs 
(absenteeism, decreased quality of life).3 These costs correlate with the fact that AD comprises a 
great deal of healthcare visits each year. Although precise census data are not available for recent 
years, it is estimated that 75% of individuals with AD visited a physician at least once in the last 
year with AD being the prime focus of their visit.3 
 The heavy burden endured by practitioners and patients in treating AD is evident. 
However, the exact cause of AD remains unknown.  Current leading research points to a 
mutation in the gene that produces filaggrin, a protein that maintains the integrity of the 
superficial-most layer of skin.2,4 Without fully functional filaggrin, there is a greater propensity 
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for the entrance of allergens and microbes coupled with greater loss of moisture, resulting in skin 
that becomes dry easily and is more susceptible to infection.2,4 It is also thought that AD 
develops from an excess of T helper 2 cells relative to T helper 1 cells, leading to an increase in 
IgE and interleukins.2 This manifests in the patient as symptoms of dry, scaly skin, erythema, 
pruritus, and open, crusty, or “weepy” sores.4 
 There are various methods of treating AD with each having specific indications. One of 
the more common treatment modalities is the use of corticosteroids which can be administrated 
topically or orally, with the latter being reserved for severe cases.2 Corticosteroids are indicated 
for symptom reduction after an exacerbation and are not indicated for prevention of acute 
episodes; however, there are a variety of preventative methods to reduce the occurrence of flares. 
Skin hydration and emollients coupled with the avoidance of allergens and irritants are effective 
towards preventing acute flares of AD. Less frequently used methods to treat AD include 
Narrowband Ultraviolet B (UVB) Phototherapy and biologics/immunosuppressants such as 
dupilumab.4 
Unfortunately, there is currently no cure for AD. The treatment modalities listed above 
play an effective role in preventing or reducing sequelae of flares, but AD is a recurrent 
condition that may be a lifelong source of emotional stress on the patient. The treatment methods 
are also not entirely benign as corticosteroids have a variety of undesirable side effects such as 
stretch marks, and hypopigmentation and atrophy of skin, especially with prolonged use.4 
Narrowband UVB phototherapy has a success rate of 70% in temporarily “remitting” AD, but it 
is primarily used for widespread or refractory AD so the application is limited.4 While biologics 
such as dupilumab have shown efficacy, there are a variety of barriers such as high out-of-pocket 
costs, requirements to fail lower forms of therapy, and the necessity of prior authorization.4 
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These are only some of the many reasons why probiotics have gained a great deal of traction as 
an adjunctive therapy option to reduce symptoms of AD. 
Probiotics have recently been targeted as a potential form of therapy in reducing AD 
symptoms. One of the main reasons is due to the immunological benefits of probiotics. Research 
has shown that AD patients tend to have a decreased innate immune response when compared 
with similar skin conditions such as psoriasis.1 The microflora in the human gut has a significant 
role in maintaining healthy immune function and as such, probiotics must be considered as a 
method to improve this function. This paper evaluates three double-blind, placebo-controlled, 
randomized controlled trials (RCTs) comparing the efficacy of various probiotic mixtures as a 
potential treatment option for reduction of AD symptoms. 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not probiotics are 
effective in reducing symptoms of atopic dermatitis. 
METHODS 
 Three double-blind, placebo-controlled RCTs were used in this study. The criteria to 
select these studies included patients greater than 1 year of age with symptomatic moderate-to-
severe atopic dermatitis. The interventions used in two of the studies were oral probiotic 
mixtures,2,5 while one study used a probiotic sachet.2 The treatment group receiving the probiotic 
mixture was compared to the control group who received a visually matched placebo. 
 All of the articles used in this study were published in peer-reviewed journals and 
selected based on patient-oriented evidence that matters (POEMs) along with relevance to the 
proposed clinical question. The articles were found by using the keywords “atopic dermatitis” 
and “probiotics” via PubMed literature search. Only studies written in English were included in 
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this review. The inclusion criteria included RCT, placebo-controlled, double-blind studies 
published after 2009. The exclusion criteria included any patients under the age of 1 and those 
with mild AD. 
 All three studies included in this systematic review used continuous data. The statistics 
that were reported included change in mean from baseline and p-values. The Mann-Whitney U 
test was used to assess Scoring of Atopic Dermatitis (SCORAD), Infant Dermatitis Quality of 
Life (IDQOL), and Dermatitis Family Impact (DFI) scores in one of the studies.5 Table 1 
illustrates the demographics and characteristics of the reviewed studies. 
Table 1: Demographics and Characteristics of Included Studies. 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/
D 
Interventions 
Gerasi- 
mov5 
(2010) 
Double 
blind 
RCT 
90 1-3 -Patients aged 1-3 years 
old with moderate to 
severe AD 
-Parent or legal 
guardian must 
comprehend study 
requirements and 
provide informed 
consent 
-Direct telephone 
access 
-Mild AD 
-Clinically 
evident bacterial 
lesions 
-Use of systemic 
corticosteroids 
-Food allergy 
besides egg or 
cow’s milk 
-Concomitant 
disease 
requiring 
immunosuppress
ants or allergic 
reactions 
 
6 Probiotic 
mixture 
(Lactobacillu
s acidophilus 
DDS-1 and 
Bifidobacteri
um lactis 
UABLA-12 
with fructo-
oligosacchari
de in a rice 
maltodextrin 
powder) 1 g 
BID 
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Iemoli6 
(2012) 
Double 
blind 
RCT 
48 -Group 
A: 
32.44 + 
1.47 
-Group 
B: 
30.91 + 
2.79 
-Adult men and women 
with moderate to severe 
AD 
 
-Probiotic, 
antibiotic, or 
immune 
modulating 
agent usage 6 
months before 
the study 
-Oral steroid 
treatment usage 
1 month before 
enrollment 
 
2 Probiotic 
mixture 
(Lactobacillu
s salivarius 
and 
Bifidobacteri
um breve 
combination) 
matched for 
size, shape, 
and volume - 
BID 
 
Navarro
-Lopez2 
(2018) 
Double 
blind 
RCT 
50 4-17 -AD meeting the 
Hanifin and Rajka 
criteria and moderate 
SCORAD index who 
had been prescribed 
topical steroids 
-Current diet with a 
Mediterranean Diet 
Quality Index 
(KIDMED) score >7 
-Written informed 
consent from parents or 
a legal representative 
(and the child if >12 
years) 
 
-Systemic 
corticosteroid, 
methotrexate, 
cyclosporine, or 
anti-TNF drug 
use in the past 3 
months, 
antibiotics in the 
past 2 weeks, or 
concomitant 
diagnosis of 
gluten and/or 
lactose 
intolerance or 
bacterial 
infection. 
3 Probiotic 
(Bifidobacter
ium lactis 
CECT 8145, 
B longum 
CECT 7347, 
and 
Lactobacillus 
casei CECT 
9104) QD 
 
OUTCOMES MEASURED 
Each of the three studies assessed changes in objective and subjective findings between 
the probiotic and placebo group using the SCORAD index which was calculated with the 
following formula: A/5 + 7B/2 + C.5 Objective findings included characteristics such as extent 
and intensity of AD, while subjective symptoms included elements such as pruritus and sleep 
loss. The SCORAD index questionnaire assessed the severity of AD, categorizing them as mild, 
moderate, or severe. Each study had differing values indicating the severity of AD. For instance, 
Gerasimov et al. categorized any score between 25-50 as moderate AD, while a score above 50 
indicated severe AD.5 This study also implemented IDQOL and DFI questionnaires for the test 
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subjects to complete. These questionnaires included ten questions specific to the infant or family 
activity over the course of the previous week with each answer being graded from 0-3. A 
minimum score of 0 and a maximum score of 30 is possible with the maximum score indicating 
the worst quality of life or the greatest family impact.5 Lastly, corticosteroid use was documented 
by the participants. 
 In the Lopez et al. study, the SCORAD index was assessed with a score of 20-40 
indicating moderate AD. These were measured at the time of inclusion and every 4 weeks until 
the end of follow-up period at week 12. As it was performed in the study by Gerosimov et al., 
this study measured the proportion of days that a topical steroid was used during flares within the 
same 12 weeks of follow-up. A flare was defined as the use of a corticosteroid for at least 3 
consecutive days and any corticosteroid use occurring less than 3 days was not included.2 
 In the Iemoli et al. study, the SCORAD index was scored as follows: 0-15 indicated mild 
AD, 16-40 indicated moderate AD, and any score above 40 indicated severe AD.6 Another 
outcome that was assessed was the Dermatology Quality of Life (DLQ) index which was 
performed by the patient. The DLQ index has a minimum score of 0 and a maximum score of 30. 
It is a 4-point scale ranging from 0-3 in which 0 indicates not at all, 1 indicates a little, 2 
indicates a lot, and 3 indicates very much.6 
RESULTS 
 All three RCT studies evaluated the effectiveness of various probiotic mixtures compared 
to placebo on individuals with moderate-to-severe AD. Placebos in these studies were identical 
to the probiotic in characteristics such as taste, smell, and/or visual appearance. Patients were 
excluded if they had previously used antibiotics, immunomodulators, or systemic corticosteroids 
in any of these studies.2,5,6 Continuous data were used for all three experiments and not 
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convertible to dichotomous format. Each study determined data to be statistically significant if 
the p-value was <0.05.  
Two trials mentioned compliance with only one of those studies providing statistical 
evidence.5 Gerasimov et al. reported that the placebo and probiotic group were 95% and 92% 
compliant, respectively, with both groups receiving more than 90% of available doses 
(p=0.723).5 This statistic was calculated through parental report and by measuring the probiotic 
and placebo powder which remained at the end of the trial. Ieomoli et al. reported that 
compliance was evaluated through a dose count but omitted results of such findings. Two trials 
were in children over the age of 1, while one trial exclusively included adults. 
The Gerasimov et al. study included children between the age of 1-3 with moderate-to-
severe AD. Direct telephone and informed consent from a parent or legal guardian were also part 
of the inclusion criteria as the participants were too young to provide consent on their own.5 
Individuals excluded from this study included those with mild AD, bacterial lesions that were 
clinically evident, food allergies excluding egg or cow’s milk, current systemic disease or cancer, 
and immunodefiencies.5 
The beginning of the experiment included 96 participants, however, by the week 8 mark, 
5 were lost to follow-up in the experimental group while 1 was lost in the control group.5 The 
experimental group of 43 patients received a probiotic mixture (DDS-1, UABLA-12 with fructo-
oligosaccharide) twice a day for 8 weeks while the control group of 47 patients received a 
placebo twice a day for 8 weeks.5 SCORAD, IDQOL, DFI, and corticosteroid use were 
documented to evaluate the effectiveness of the probiotic in reducing symptoms of AD. 
Statistical significance was observed when comparing SCORAD, IDQOL, and DFI at baseline 
and week 8 of the trial (p=0.001. p=0.013, and p=0.010, respectively). This study found a 
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statistically significant reduction in SCORAD at the end of the trial when assessing exclusively 
subjective symptoms (pruritus, sleep loss). These findings fall in line with the overall SCORAD 
decrease of 33.7% and 19.4% in the probiotic and placebo group, respectively.5 However, there 
was no statistical significance with corticosteroid use per week (p=0.130) when comparing 
baseline and week 8 findings.5 These findings are illustrated in Table 2 below. 
Table 2: Change in mean at baseline and week 8 (Gerosimov et al.) 
 Time 
Period 
Probiotic (SD) Placebo (SD) p-value 
SCORAD* Baseline 8.7 (2.9) 8.0 (2.4) 0.001 
 Week 8 -3.0 (2.7) -1.4 (2.0)  
IDQOL Baseline 11.2 (4.4) 12.1 (3.6) 0.013 
 Week 8 -3.7 (3.3) -2.3 (1.6)  
DFI Baseline 12.2 (4.0) 12.6 (4.7) 0.010 
 Week 8 -4.3 (1.7) -3.0 (2.7)  
Corticosteroid use Baseline 1.9 1.7 0.130 
 Week 8 0.8 1.2  
*Assessing subjective symptoms (pruritus, sleep loss) 
SD = standard deviation 
 
The Iemoli et al. study included adult men and women with moderate-to-severe AD in 
the setting of a hospital allergy unit. Individuals were excluded from the study if they had used 
probiotics 6 months prior to the trial. A total of 48 patients were enrolled in the study and 
separated into a probiotic and placebo group in a 2:1 ratio. A single patient was lost from each 
group. The experimental group of 32 patients were administered with a probiotic mixture (LS01 
and BR03 strains) taken twice daily for 12 weeks. The control group of 16 patients took a 
placebo (maltodextrin) with the same regimen. 
The SCORAD and DLQ questionnaire were addressed in this study with changes noted 
in the probiotic and placebo group when compared at baseline to week 12 of the study. The 
SCORAD at baseline for the probiotic group (46.25 +/- 3.70) and placebo group (45.00 +/-2.60) 
were decreased at week 12 to 29.45 +/- 2.01 and 40.21 +/- 1.53, respectively.6 The probiotic 
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group had significant decreases in SCORAD and DLQ at the end of treatment (p = 0.001, p = 
0.024, respectively) and even 2 months after treatment (p = 0.006, p = 0.001, respectively).6 The 
placebo group had no significant differences. 
The Lopez et al. study was performed in an outpatient hospital and included children 
between age 4-17 years old with moderate AD. It was required for participants to be currently on 
a high-quality Mediterranean diet validated through the Mediterranean Diet Quality Index 
(KIDMED). As with the previous study, participants required written consent from the parent or 
legal representative due to age. Those excluded from the study included intolerance to gluten or 
lactose as well as signs of bacterial infection.2  
The study began with 50 participants, however, 2 were lost to follow-up at the 8-week 
mark, while 1 was lost at the 12-week follow-up in the experiment group. This study examined 
the change in SCORAD score and corticosteroid use between the experimental and control 
group. The experimental group of 26 patients were instructed to take a probiotic (CECT 
8145, CECT 7347, and CECT 9104) once daily for 12 weeks.2 The control group of 24 patients 
took a placebo (maltodextrin) once daily for the same amount of time and was matched in 
appearance and route of administration to the probiotic. Lopez et al. reported a significant 
improvement in the total SCORAD score among the probiotic group when compared to the 
placebo group. The total SCORAD combined objective findings (intensity and spread of eczema) 
and subjective symptoms (pruritus, sleep loss) in the report. However, subjective symptoms are 
the only factor of statistical importance in this review. There was an insufficient amount of data 
provided in this study as the only conclusive finding was a report of no statistically significant 
difference in subjective symptoms between the probiotic and placebo group. 
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Lopez et al. found a statistically significant reduction in the use of corticosteroids during 
flares among the probiotic group. An adjusted logistic regression model was used to calculate the 
odds ratio (OR) to be 0.63 with a confidence interval (CI) of 95% [0.51 to 0.78]. The data 
favored probiotics even when a sensitivity analysis was performed to account for steroid use 
which included non-flare scenarios (defined as less than 3 consecutive days of corticosteroid 
use). In this situation, the placebo and probiotic arm had 336 (16.5%) and 291 (14.0%) days of 
steroid use, respectively.2 In this case, the OR was 0.77 with a CI of 95% [0.65 to 0.91] and p-
value <0.003. The findings are illustrated in Table 3 below. 
Table 3: Corticosteroid use in a flare (Lopez et al.) 
 Patient-days of 
observation 
Days of steroid 
use to treat 
flares 
Odds Ratio; 
[CI 95%] 
p-value 
Probiotic 2084 161 (7.7%) 0.63 [0.51 to 
0.78] 
<0.001 
Placebo 2032 220 (10.8%)   
 
DISCUSSION 
 Probiotics offer a safe option in reducing symptoms of AD as they have an extensive 
history of being safe to use in healthy individuals.7 In fact, of the three studies in this review, 
only one mentioned adverse effects such as diarrhea, constipation, and upper respiratory 
infection with none of these being linked to the probiotics used in the study.5 The exception to 
safe probiotic use is with severely ill and immunocompromised individuals who may experience 
greater side effects.7 
 In the review of these studies, a major limitation was in the assessment of the SCORAD 
index. The SCORAD evaluates objective findings, or disease-oriented outcomes, in addition to 
subjective symptoms, patient-oriented outcomes. For the purpose of this review paper, the latter 
is the focus which includes effects on pruritus and sleep loss. The combination of both categories 
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of symptoms makes it difficult to assess whether subjective, patient-oriented outcomes are truly 
being improved with the use of probiotics. Only two of the three studies in this review separated 
subjective and objective elements of the SCORAD with one of those studies finding statistically 
significant reduction in subjective symptoms,5 and the other noting insignificant symptom 
reduction between the probiotic and placebo group.2 
It is important for studies to control outside factors that can influence the results of a 
study. This was seen in the Lopez et al. study which mandated a high-quality Mediterranean diet. 
However, the data could have been more accurate with diary documentation of additional habits 
that may influence the course of AD such as exercise, brand of laundry detergent or soaps, and 
even moisturizing routine. These are all precipitating factors that have been proven to cause 
acute exacerbations of AD.4 It is apparent that these controls would be more difficult in studies 
exclusively involving children as it would require a great deal of compliance and responsibility 
in the hands of both the participant and the parent or legal representative. 
CONCLUSION 
 These studies provide evidence that probiotics can be used as an effective adjunctive 
therapy in those with moderate-to-severe AD. While it will not have efficacy as monotherapy, 
the studies in this review have demonstrated a reduction of symptoms when taken along with 
other standard medications such as topical corticosteroids.  In addition to being effective in 
reducing symptoms, it was also shown to significantly reduce the need for corticosteroid use in 
two of the studies.2,5 While all three of these studies found improvement in SCORAD overall, 
more research must be done focusing strictly on subjective symptoms given that this index also 
factors in objective signs. 
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